Search
Levomefolic acid
go.drugbank.com/drugs/DB11256ApprovedLevomefolic acid (INN) is the metabolite of folic acid (Vitamin B9) and it is a predominant active form of folate found in foods and in the blood circulation, accounting for 98% of folates in human plasma … It is transported across the membranes including the blood-brain barrier into various tissues where it plays an essential role in the DNA synthesis, cysteine cycle and regulation of homocysteine, where
Synonyms: N-[4-[[[(6S)-2-Amino-3,4,5,6,7,8-hexahydro-5-methyl-4-oxo-6-pteridinyl]methyl]amino]benzoyl]-L-glutamic acidMixtures: Medi-10, PNV Tabs 20-1Zongertinib
go.drugbank.com/drugs/DB18762ApprovedInvestigational[L53873,A274363] On August 8, 2025, the US FDA granted accelerated approval to zongertinib for the treatment of advanced forms of non-small cell lung cancer (NSCLC) with HER2 tyrosine kinase domain … [L53873,A274363] It covalently binds to the HER2 receptor, including exon 20 insertions, and inhibits downstream signaling pathways while sparing wild-type epidermal growth factor receptor (EGFR), which
Recombinant stabilized RSV A prefusion F antigen
go.drugbank.com/drugs/DB18713ApprovedInvestigational[L48066] Abrysvo was first approved by the FDA in May 2023 for use in patients ≥60 years of age, and received subsequent approval in August 2023 for use in pregnant individuals for the protection of … [L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in December 2023.
Irofulven
go.drugbank.com/drugs/DB05786InvestigationalPhase III clinical trials involving the drug have been underway since early 2001 at sites in the U.S. and Europe. … MGI-114 (Irofulven) is currently being developed by MGI PHARMA, Inc., an emerging oncology-focused pharmaceutical company based in Minneapolis.
Ledipasvir
go.drugbank.com/drugs/DB09027ApprovedIts use has also proven successful in the treatment of HCV in patients co-infected with HIV [A19627]. … In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend ledipasvir as a first line
Mixtures: HARVONI 90 MG/400 MG FILM KAPLI TABLET, 84 ADET, HARVONI 90 MG/400 MG FILM KAPLI TABLET, 28 ADETChlorobutanol
go.drugbank.com/drugs/DB11386ApprovedVet approvedWithdrawnChlorobutanol, or chlorbutol, is an alcohol-based preservative with no surfactant activity [A32746]. … Similar in nature to chloral hydrate, it is formed by the simple nucleophilic addition of chloroform and acetone.
Mixtures: DİŞİNOL 2 G + 0,5 G + 3,5 G/10 ML ÇÖZELTİ, NOSTIL 75 MG/60MG/35MG BURUN SPREYİ, ÇÖZELTİ, 15 MLCategories: Compounds used in a research, industrial, or household settingTalimogene laherparepvec
go.drugbank.com/drugs/DB13896ApprovedInvestigationalTalimogene laherparepvec is an oncolytic treatment used in local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with recurrent melanoma. … It is a genetically administered herpes simplex virus 1 (HSV-1) that expresses human cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with antitumor and immune-stimulating activities.
Categories: Complex MixturesAzaperone
go.drugbank.com/drugs/DB11376InvestigationalVet approvedMore rarely it may be used in humans as an antipsychotic drug, but this is uncommon.
Products: AZANIL 40MG/ML INJECTIONCoagulation factor X human
go.drugbank.com/drugs/DB13148ApprovedInvestigationalCoagulation Factor X (Human) solution is approved by the FDA for intravenous injection under the market name Coagadex which contains normally 100 IU/mL of coagulation Factor X derived from healthy donors … However its use is limited in the perioperative setting for the management of bleeding in major surgery in patients with moderate and severe hereditary Factor X deficiency.
Mixtures: COFACT 250 IU/10 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET, COFACT 500 IU/20 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADETDamoctocog alfa pegol
go.drugbank.com/drugs/DB14700ApprovedInvestigational[L4576,A38909] This product has been engineered by Bayer[L4576] and a biological license application has been filed with the FDA in August 2017 and FDA approved in August 2018.[F1609] … In recent years, various extended half-life factor VIII and factor IX preparations have been studied and gained approval.